Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in melanoma, dashing its hopes of moving the drug earlier in the treatment pathway ...

Nuvalent chases after Nuvation in ROS1 lung cancer. New trial data sets up a filing for Nuvalent's new-generation ROS1 inhibitor in NSCLC, although it has an uphill battle to catch rival Nuvation.

Before the 35th anniversary of one of the world's deadliest plane crashes, Machiko Taniguchi wrote a letter to Boeing Co., the manufacturer of the ill-fated commercial jetliner.

NPR's brings you news about books and authors along with our picks for great reads. Interviews, reviews, and much more.